Gene therapy offers another potential cure for SCD, but concerns over the safety of random genomic insertion need to be resolved [74]. SCD is a complex disorder

with considerable variability among individuals and accumulating morbidities associated with aging, which challenge its management. Furthermore, few treatments exist for SCD, and the primary treatment (HU) is significantly underused. Internationally, focus needs to continue on instituting newborn screening in low-resource countries, point-of-care signaling pathway testing, and early childhood care to prevent early morbidity. Additionally, although comprehensive management programs exist for paediatric patients with SCD, there is a need for improved transition of care to reduce early mortality in young adults and to reduce hospital utilisation costs

by preventing over-reliance on acute care facilities. Although curative options with HSCT exist for SCD, they still remain limited due to a lack of appropriate donors and concerns with procedural toxicities. In high-resource countries, comprehensive coordinated care for adults Alpelisib supplier with SCD remains a priority. Until adult patients with SCD have access to acceptable preventative care services and specialised management centres, they will continue to receive suboptimal care at unnecessarily high cost. The model of care of patients with sickle cell disease (SCD) should be preventative and comprehensive in addition to acute care management. Identification and application of biomarkers of disease severity

in sickle cell disease Funding for editorial assistance was provided by the Novartis Pharmaceuticals. Dr. Julie Kanter-Washko is an employee of the Medical University of South Carolina, which has received research funds from Novartis unrelated to the publication of this manuscript. At her previous institution (Tulane University School of Medicine), she received research funds from Emmaus pharmaceuticals and Eli Lilly pharmaceuticals also unrelated to this manuscript. Dr. Kruse-Jarres is an employee of Tulane University, which has received research funds from Novartis unrelated to the publication of this manuscript. Both authors have contributed to the writing of this review Farnesyltransferase manuscript and have had full access to the references used. Under the direction and supervision of the authors, medical writing and editorial assistance was provided by Susan M. Cheer, PhD and Susan M. Kaup, PhD of Envision Pharma Group, and funded by the Novartis Pharmaceuticals Corporation. The authors received no funding from Novartis Pharmaceuticals Corporation. “
“The importance of iron as well as of iron metabolism has been largely neglected in the transfusion medicine community, even if isolated investigators have made important contributions in this field [1], [2], [3], [4], [5], [6], [7], [8] and [9].